U.S. panel to review restrictions on Roche's Accutane

02/26/2004 | Reuters

The FDA will ask an outside panel of experts if tougher restrictions are needed on the use of Accutane, a highly effective prescription drug against acne but one that also can cause birth defects. The panel will review new data showing efforts to keep pregnant women from taking the drug with strongly worded warnings and controls have fallen short. A Roche spokeswoman said the drug maker has proposed new restrictions and will consider the advice of the panel.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA